Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616055 · ClinicalTrials.gov registry record · Phase 2
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
A Phase 2 study, sponsored by Kadmon Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02616055 is a Phase 2 study that was terminated before completion, run by Kadmon Corporation. The registered enrollment target is 15 participants.
The verdict
NCT02616055, a Phase 2 study, was terminated before completion, sponsored by Kadmon Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Subjects who received tesevatinib in Study KD019-101 and completed 24 months of treatment will continue on the dose of tesevatinib they were receiving at 24 months on the KD019-101 study.
Interventions
- DRUG tesevatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-12-25 |
| Est. Completion | 2016-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02616055
The ClinicalTrials.gov registry entry for NCT02616055 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kadmon Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tesevatinib is the first listed.
NCT02616055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02616055 about?
NCT02616055 is a clinical study titled "Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101". Subjects who received tesevatinib in Study KD019-101 and completed 24 months of treatment will continue on the dose of tesevatinib they were receiving at 24 months on the KD019-101 study.
What is the current status of trial NCT02616055?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2015-12-25. Estimated completion is 2016-12-21.
What interventions are being tested in trial NCT02616055?
The interventions under investigation include: tesevatinib (DRUG).
Who is sponsoring clinical trial NCT02616055?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.